诺和诺德表示，按固定汇率计算的销售增长预期从此前的13%-21%下调至8%-14%，营业利润增长预期从16%-24%下调至10%-16%。主要原因是其旗舰减肥药物 Wegovy 在现金支付渠道的销售表现低于预期，受到“不安全且非法的大规模仿制药”冲击。受此消息影响，诺和诺德周二收跌近22%，盘中一度跌28%，创2022年2月以来新低。候任CEO Doustdar表示，未来将更关注成本，重拾绩效文化...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.